Trials / Completed
CompletedNCT00672477
Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness And Opioid-Induced Constipation: Efficacy, Safety, And Additional Health Outcomes
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 237 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. The hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylnaltrexone | |
| DRUG | Placebo |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2008-05-06
- Last updated
- 2018-03-08
- Results posted
- 2018-03-08
Locations
60 sites across 12 countries: United States, Australia, Belgium, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00672477. Inclusion in this directory is not an endorsement.